In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii

Revista Iberoamericana de Micologia

Volumn 16, Issue 1, 1999, Pages 36-39

  De Bedout, Catalina ^a   Ordóñez, Nelly ^b   Gómez, Beatriz Lucia ^a   Rodríguez, María Claudia ^c   Arango, Myrtha ^a   Restrepo, Angela ^a   Castañeda, Elizabeth ^b  

^a Unidad de Biología Celular y Molecular   (Colombia)

^b INSTITUTO NACIONAL DE SALUD   (Colombia)

^c Hospital Erasmo Meoz   (Colombia)

Author keywords

Cryptococcus neoformans var. gattii; Cryptococcus neoformans var. neoformans; Minimal inhibitory concentration (MIC); Resistance; Susceptible; Susceptible dose dependent

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CRYPTOCOCCUS NEOFORMANS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE;

EID: 0032944934     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Haijeh R, Branct M, Pinner W. Emergence of cryptococcal disease: Epidemiologic perspectives 100 years after its discovery. Epidemiol Rev 1995; 17:303-320.
2. Kwon-Chung KJ, Bennett JE, Theodore TS. Cryptococcus bacillisporus sp. nov serotype B-C of Cryptococcus neoformans. Int J Syst Bacteriol 1978; 28:616-620
3. Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 1984; 120:123-130.
4. th Congress of the International Society for Human and Animal Mycology. Salsomaggiore Terme, Parma, Italy, 1997: P168.
5. Speed B, Dunt D. Clinical and host differences between infection with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21:28-34
6. Fromtling RA, Abruzzo GK, Bulmer GS. Cryptococcus neoformans. comparison of in vitro antifungal susceptibilities of serotypes AD and BC. Mycopathologia 1986; 30;27-30.
7. Peach PR, Pharm D, Paul O, et al The association between cryptococcal variety and immunocompetent hosts. Pharmacotherapy 1998; 18: 255-264.
8. Peetermans SW, Bobbaers H, Verhaegen J, Vandepitte J. Fluconazole-resistant Cryptococcus neoformans var gattii in an AIDS patient. Acta Clin Belg 1993; 48:405-409.
9. Kreger Van Rij. The yeasts: a taxonomic study (3rd ed.). Amsterdan, Elsevier Science Publisher, 1984:472-482.
10. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var neoformans (serotypes A and B) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 1982; 15 535-537
11. National Committee for Clinical and Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of yeasts; proposed standards, M27-A. Villanova, Pa., National Committee for Clinical Laboratory Standards, 1997.
12. Nguyen MH, Yu CY. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole susceptible and resistant Cryptococcus neoformans isolates Antimicrob Agents Chemother 1998; 42:471-472.
13. Vanden Bossche H, Dromer F, Improvisi I, et al. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36 (Suppl. 1): 119-128.
14. Lozano-Chiu M, Paetznick, VL, Ghannoum MA, Rex JH. Detection of resistance to amphotericine B among Cryptococcus neoformans clinical isolates: Performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol 1998; 2817-2822
15. White DH, Armstrong D. Cryptococcosis: Infect Dis Clin North Am 1994; 8: 383,398.
16. Powderty WG, Keath EJ, Sokol-Anderson M. Amphotericin B resistant Cryptococcus neoformans in patient with AIDS Infect Dis Clin Pract 1990; 1:314-316
17. Joseph-Horne RS, Loeffler RST, Hollomon DW, Kelly SL. Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis J Med Vet Mycol 1996; 34:223-225.
18. Witt, MD, Lewis, RJ, Larsen, RA, et al Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing. Clin Infect Dis 1996; 22: 322-328.
19. Alves SH, Lopes JO, Costa JM, Klock C. Development of secondary resistance to fluconazole in Cryptococcus neoformans isolated from a patients with AIDS. Rev Inst Med Trop São Paulo 1997; 39:359-361.
20. Armengou A, Porcar C, Macaró J, Garcia-Bragado F. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996, 23:1337-1338.
21. Paugom A, Dupauy-Camet P, Blache JP, et al. Increased fluconazole resistance of Cryptococcus neoformans isolated from patients with AIDS and recurrent meningitis. Clin Infect Dis 1994; 19:975-976.
22. Espinel-Ingroff E, Barchiesi F, Hanze KC, et al. Standardization of antifungal susceptibility testing and clinical relevance. Med Mycol 1998; 36 (Suppl 1).68-78.
23. Nguyen MH, Barchiesi F, McGough DA, et al. in vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus nepformans var neoformans. Antimicrob Agents Chemother 1995; 39:1691-1695
24. Vélez JD, Allendoerfer R, Luther M, et al. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis 1993; 168:508-510.
25. Berg J, Clancy CJ, Nguyen H. The hidden danger of primary fluconazole prophylaxis for patients with AIDS Clin Infect Dis 1998; 26:186-187.
26. Meninchetti F, Fioro M, Tosti A. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22:838-840.
27. Franzot SP, Hamdam JS. in vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs. Antimicrob Agents Chemother 1996; 40: 822-824.